Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNTH312
- Development stage
- Preclinical
- Lead developer
- Dianthus Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
DNTH312 is an investigational, first-in-class, next-generation bifunctional fusion protein developed by Dianthus Therapeutics for the treatment of severe autoimmune diseases. It is designed to simultaneously inhibit two validated pathways: the classical complement pathway by blocking active C1s (aC1s), and B-cell activity by blocking BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). The molecule combines claseprubart (an active C1s antibody) with TACI (transmembrane activator and CAML interactor) and is enhanced with YTE half-life extension technology to enable infrequent subcutaneous self-administration. DNTH312 is aimed at autoantibody-mediated diseases such as myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN), with plans to expand into other autoimmune and rheumatology indications. Dianthus Therapeutics aims to have DNTH312 Phase 1 ready by the end of 2027.
- Other names
- DNTH-312DNTH312DNTH 312claseprubart-TACIclaseprubart-TACI fusion constructclaseprubart-TACI fusion protein
02
Targets
C1S (Complement component 1s subcomponent serine protease)TNFSF13 (APRIL)BAFF (Tumor necrosis factor ligand superfamily member 13B)
Beyond the preview
Go deeper on DNTH312.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNTH312.